Details of the Drug

General Information of Drug (ID: DM3274D)

Drug Name

Fostamatinib disodium

Synonyms

1025687-58-4; R788(prodrug of R406); R788 (Fostamatinib) Disodium; UNII-X9417132K8; R 788 sodium; R788(Fostamatinib disodium); R 935788 sodium; R935788 (Fostamatinib disodium, R788); R788 disodium; X9417132K8; R788 disodium hexahydrate; R788 SODIUM; R-788 disodium; R788, Fostamatinib; Tube731; sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate; Disodium (6-(5-fluoro-2-(3

Indication

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Phase 3	[1]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
2

Molecular Weight

624.4

Topological Polar Surface Area

Not Available

Rotatable Bond Count

9

Hydrogen Bond Donor Count

2

Hydrogen Bond Acceptor Count

15

Chemical Identifiers

Formula: C23H24FN6Na2O9P
IUPAC Name: disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate
Canonical SMILES: CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+]
InChI: InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
InChIKey: HSYBQXDGYCYSGA-UHFFFAOYSA-L

Cross-matching ID

PubChem CID: 25008120
CAS Number: 1025687-58-4
TTD ID: D00OPX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Thrombocytopenia

ICD Disease Classification

3B64

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase SYK (SYK)	DTT	SYK	5.20E-02	-0.57	-0.67

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
3	Company report (Portola Pharmaceuticals)
4	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
7	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
8	Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)